Key Dates

Abstract Submission Opens:

November 5 (Tue.), 2024

Abstract Submission Deadline:

December 24 (Tue.), 2024
Extended to January 14 (Tue.), 2025
We deeply appreciate for Submitting Abstracts.
Abstract Submission has closed.

Categories

General Presentation

• 1. Basic research on etiology, pathogenesis, and treatment
• 2. Immune microenvironment
• 3. Diagnostic methods (e.g., prognostic factors, biomarkers, MRD measurement)
• 4. First line treatment of myeloma
• 5. Treatment of relapsed/refractory myeloma
• 6. Novel therapies of myeloma (e.g., CAR-T therapy)
• 7. Response/risk-adapted therapy
• 8. Myeloma-related disorders
• 9. Prevention and management of infectious diseases
• 10. Evaluation and management of myeloma-associated bone diseases
• 11. Management of elderly myeloma patients
• 12. Cancer rehabilitation
• 13. Regional medical cooperation for elderly myeloma patient care (e.g., home nursing, home medical care, out-of-hospital pharmacies)
• 14. Complications/Supportive care
• 15. Case report
• 16. Others

Additional Abstract Categories other than General Presentation

(A) Late-Breaking Abstracts (LBA)

Submission Period:

December 17 (Tue.), 2024 -

February 11 (Tue.), 2025 (Planned)
We deeply appreciate for Submitting Abstracts.
Abstract Submission has closed.

*

Please refer to▼the application guideline of Late-Breaking Abstract.

Late-Breaking Abstracts

• 1)We understand that it may not be possible for abstracts authors to meet JSM Annual Meeting general presentation abstract submission deadline when presentation contents relate to particularly high-value clinical trials. Therefore, we call for Late-Breaking Abstracts for such cases.
• 2)Submissions for this category will be accepted until the absolute final deadline for JSM Annual Meeting submissions. They will not be included in the printed collection of abstracts, but will be included in the digital program collection.
• 3)There is a limit to the number of submissions accepted in this category.
• 4)Submission requirements are as follows:
  
  • i. The reason(s) for not submitting by the general presentation abstract submission deadline must be deemed acceptable by reviewers, and the submission must exhibit high potential in regard to its scientific value.
  • ii. The primary author and any other co-author who will participate in the meeting must pay their registration fees for the JSM Annual Meeting. No fee payments will be refunded, regardless of selection results.
  • iii. No objection in response to review results will be recognized, regardless of selection results and any other factor.
  • iv. In all other respects, submissions must be made in accordance with rules for general presentation submissions.

*

If you submit for both “General Presentation” and “Late Breaking Abstract”, it will be reviewed as “General Presentation”.

(B) Trials in Progress (TiP)

*

Please refer to▼the application guideline of Trial in Progress.

Trials in Progress (TiP)

• 1)The TiP category is established for the sake of planned and currently-underway clinical research and other such activities (with a primary focus on clinical research) that have not yet produced analytical or other results and which, through their presentation and discussion at the JSM Annual Meeting, exhibit potential for higher-value influence and impacts based on methodologies and research progress moving forward.
• 2)The submission deadline is the same as for general presentation submissions.
• 3)There is a limit to the number of submissions accepted in this category.
• 4)Submission requirements are as follows:
  
  • i. The research in question for submission in this category must be fully planned and/or currently underway, with primary endpoint analysis not yet completed at the time of submission.
  • ii. Discussions in this category are expected to enable early involvement by translational researchers, biostatisticians, regulatory specialists and other such researchers in research efforts at clinical facilities, in corporate-led clinical case studies and similar. Furthermore, this category has the potential to promote greater numbers of case studies through increased visibility for ongoing clinical research.
  • iii.The primary author and any other co-author who will participate in the meeting must pay their registration fees for the JSM Annual Meeting. No fee payments will be refunded, regardless of selection results.
  • iv. No objection in response to review results will be recognized, regardless of selection results and any other factor.
  • v. In all other respects, submissions must be made in accordance with rules for general presentation submissions.

(C) Encore Abstract

*

Please refer to▼the application guideline of Encore.

Encore Presentation

• 1)An abstract which, at the time of submission, is identical to or nearly unchanged from (an adaptation of) an abstract presented previously at a major overseas conference or similar event within one year prior to this Annual Meeting, but which has not been presented yet at past JSM Annual Meetings or other conferences or similar events in Japan, may be submitted in this category.
• 2)There is a limit to the number of submissions accepted in this category.
• 3)Submission requirements are as follows:br>
  • i. Abstracts in this category must have potential to gain new, highly meaningful scientific value through submission to and fresh discussion at the JSM Annual Meeting.
  • ii. The phrase “(Encore)” must be added to the end of the abstract’s title.
  • iii. If any copyright or similar exists for any part of the submission, the submitter is responsible for obtaining consent for submission and usage.
  • iv. In the case of copyrighted material usage, if said copyright holder is a scientific association, publishing company or similar, the final portion of the abstract must include a statement indicating that permission for copyrighted content submission and usage has been obtained as well as information on the original copyrighted material (original abstract or similar).
  • v. The primary author and any other co-author who will participate in the meeting must pay their registration fees for the JSM Annual Meeting. No fee payments will be refunded, regardless of selection results.
  • vi. No objection in response to review results will be recognized, regardless of selection results and any other factor.
  • vii. In all other respects, submissions must be made in accordance with rules for general presentation submissions.

Guideline for Abstract Submission

For participants from overseas

Participants from overseas can submit without membership status, but are required to pay the registration fee. This registration fee is NOT REFUNDABLE despite the result of acceptance/rejection of the submission. This non-refundable condition is the same for the submission by the Japanese members.
Registration is scheduled to open in February 2025

Submission Requirements

The primary author (presenter) must be a member of the Japanese Society of Myeloma. Exceptions are permitted for early-career residents in the new training system, non-M.D. graduate students, undergraduate students, international students, and non-Japanese nationals, who may present their abstracts as the primary author regardless of membership.

Presentation Format

Oral Presentation or Poster Presentation

Presentation Awards

Excellent Programs for plenaries (limited to oral presentations) and posters will be selected and awards will be presented at the closing ceremony.

JSM Travel Award for IMS/IMW

JSM Travel Award for IMS/IMW is applicable for only the Japanese JSM members. Conditions of this award appears in the Japanese page. Application forms (Application Form, Recommendation Letter, English Abstract, Research Achievements) also appears in the Japanese page.

Abstract Submission and Book of Abstracts

The abstract book will be published by the International Journal of Myeloma to preserve the contents in a format readily available for future citations.

Conflict of Interest Disclosure

All authors are required to disclose any Conflict of Interest (COI) with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript within the period of 36 months prior. The primary author is required to complete the form below with information from all the authors listed in the manuscript.

For Oral Presentations

Please show whether you have Conflict of Interest on the second slide made in accordance with the following template (example), and state it in your presentation.

For Poster Presentations

The following template (example) for Conflict of Interest disclosure should be displayed with the poster.

• Japanese Society of Myeloma COI Disclosure (example)

Consideration of research ethics, etc.

When making a presentation at the annual meeting of the Japanese Society of Myeloma, the contents of the presentation must comply with the ethical guidelines, laws and regulations in each country. When submitting an abstract, please state one of the following two options based on the status; "This presentation has been approved by an ethics committee or institution for clinical or basic research" or "This presentation does not require approval by an ethics committee or institution. If you choose the former, please indicate clearly on your presentation slide or poster that your presentation has been approved. Whether or not approval is required for a small number of case reports should be in accordance with the judgment of each institution. Researches involving off-label use must be approved prior to start of research. If "Not Applicable" is checked for the study which includes the contents considered to require approval by the Ethics Committee or the institution, the abstract may be rejected.

Abstract Submission

Please download the Abstract Submission Format (Microsoft Word) below, fill out the required fields, and submit to the Congress Secretariat of JSM2025 via E-mail（jsm2025@c.inter-plan.co.jp）

• Abstract Submission Format

• Late-Breaking
  Abstract Submission Format

Late-Breaking Abstract Submission Deadline:February 11 (Tue.), 2025

• 1. Presentation Format: Please select one of “Oral”, “Poster” or “Either”.
• 2. Category: Please select one of “Category: General Presentation”, “Late-Breaking Abstract”, “Trials in Progress” or “Encore Abstract”.
• 3. Title: less than 150 letters.
• 4. Abstract body: less than 1,600 letters = about 240 words.
  Images, charts and photographs are not allowed to include in the abstract.
• 5. First author and co-author names: No more than 20 presenters.
• 6. First author and co-author affiliations: No more than 20 affiliations.

• - All the abstracts must be submitted by using the designated format via email.
• - Abstract title, primary and co-author names and their affiliation will be printed on the abstract book as submitted. JSM2025 will not take any responsibility for errors made by the applicants.
• - Corrections of abstract title, primary and co-author names and affiliation after the deadline will not be accepted.

Regarding acceptance and rejection

• - The acceptance or rejection of the program will be determined after all review process.
• - Acceptance notification will be sent to you by email in early March.
• - The details about presentation will be announced on this website.

Contact information

Secretariat of JSM2025
(The 50th Annual Meeting of the Japanese Society of Myeloma)
E-mail：jsm2025@c.inter-plan.co.jp